Compare
Hyperbaric Oxygen Therapy (HBOT) vs Standard Wound Care
Hyperbaric oxygen therapy (HBOT) and standard wound care are not competing options; in chronic wounds, HBOT is an adjunct to a complete standard-of-care plan, and Medicare reimburses it only when standard care has been documented and is failing. Standard wound care covers the foundational work — debridement, infection control, offloading, vascular optimization, glycemic control, and dressing selection. HBOT delivers 100% oxygen at 2.0–2.5 atmospheres absolute (ATA) for 90-minute sessions inside a pressurized chamber, raising tissue oxygen tension to support angiogenesis and host defense in selected wounds. The Centers for Medicare & Medicaid Services (CMS) National Coverage Determination 20.29 spells out which conditions qualify and what documentation is required.
Educational reference · Updated 2026-04-30
Key takeaways
- HBOT is an adjunct to standard wound care, not a replacement for debridement, offloading, or infection control.
- Medicare covers HBOT under NCD 20.29 for specific indications, including Wagner grade 3+ diabetic foot ulcers that have failed at least 30 days of standard care.
- Cochrane reviews show short-term healing and amputation-reduction benefits for selected diabetic foot ulcers; evidence is strongest for radiation injury and certain emergencies.
- Untreated pneumothorax is an absolute contraindication; certain chemo agents, severe COPD with bullae, and claustrophobia are key relative cautions.
| Aspect | Hyperbaric Oxygen Therapy (HBOT) | Standard Wound Care |
|---|---|---|
| What it is | 100% oxygen delivered at 2.0–2.5 ATA inside a pressurized chamber, typically 90-minute sessions, 5 days/week, often 30–40 total treatments | Comprehensive outpatient wound management: assessment, debridement, infection control, offloading, compression, advanced dressings, vascular and metabolic optimization |
| Primary mechanism | Raises dissolved oxygen in plasma to levels capable of reaching ischemic tissue, supporting fibroblast activity, angiogenesis, leukocyte killing, and reduction of edema | Removes barriers to healing — necrotic tissue, infection, pressure, ischemia, hyperglycemia, edema — so the wound can progress through the normal healing cascade |
| Who is a candidate | Patients with a CMS NCD 20.29 covered indication (e.g., Wagner grade 3+ diabetic foot ulcer that has failed 30 days of standard care, chronic refractory osteomyelitis, soft tissue or osteoradionecrosis, compromised flap/graft) | Essentially every patient with a chronic, non-healing, or complex acute wound — there is no wound that does not benefit from a structured standard-of-care plan |
| Evidence base | Cochrane reviews show benefit for selected diabetic foot ulcers (reduced major amputation, improved short-term healing); strong evidence for radiation injury and certain emergencies | Foundational evidence — debridement, offloading (total contact cast for plantar DFU), compression for venous ulcers, and infection control are first-line per IWGDF and SVS/AVF guidelines |
| Typical setting / cost | Hospital-based or outpatient HBOT centers; significant time commitment; covered by Medicare and most insurers when NCD criteria and documentation are met | Wound clinic, primary care, home health, or hospital-based wound center; varies from low-cost office visits to hospital outpatient department fees |
| Contraindications / risks | Untreated pneumothorax is an absolute contraindication; relative cautions include certain chemotherapy agents (bleomycin, doxorubicin), severe COPD with bullae, claustrophobia, and ear/sinus disease | Few absolute contraindications; specific therapies have their own (e.g., high-pressure compression contraindicated in significant peripheral artery disease) |
How HBOT works in chronic wounds
Inside a hyperbaric chamber pressurized to 2.0–2.5 ATA, breathing 100% oxygen raises arterial oxygen tension well above what is achievable at the surface. The Undersea and Hyperbaric Medical Society (UHMS) describes the mechanisms behind HBOT — increased dissolved oxygen reaching ischemic tissue, mobilization of stem and progenitor cells, modulation of inflammatory signaling, and enhancement of leukocyte oxidative killing of bacteria. Repeated exposures over weeks support angiogenesis and granulation in wounds that have stalled under standard care alone. HBOT does not address mechanical or metabolic problems — it is layered on top of debridement, offloading, infection control, and vascular and glycemic optimization.
Medicare-approved indications and the 30-day rule
CMS National Coverage Determination 20.29 lists the conditions for which Medicare covers HBOT. For chronic wounds, the most common pathway is a Wagner grade 3 or higher diabetic foot ulcer that has failed an adequate course of standard wound care (typically documented for at least 30 days) — including assessment of vascular status, sharp debridement, optimization of glycemic control, treatment of infection, off-weighting of the affected limb, and a moisture-balanced dressing. Other covered indications include chronic refractory osteomyelitis, soft tissue radionecrosis and osteoradionecrosis, preparation and preservation of compromised skin grafts and flaps, and several acute emergencies (gas gangrene, severe carbon monoxide poisoning, decompression sickness, arterial gas embolism). Coverage is contingent on careful documentation of standard care and ongoing reassessment.
What the evidence actually shows
For diabetic foot ulcers, a Cochrane systematic review reported that HBOT, added to standard care, improved short-term ulcer healing and reduced major amputations in selected patients, while noting variability across trials. Subsequent randomized trials (including DAMOCLES) have produced mixed results, prompting clinicians to focus HBOT on patients who match the CMS criteria — Wagner grade 3+ DFU with adequate perfusion who have not progressed on optimized standard care. Evidence is stronger and more consistent for late radiation tissue injury and for certain acute emergencies (gas embolism, severe carbon monoxide poisoning, clostridial myonecrosis). Wound centers that use HBOT well integrate it with vascular evaluation, offloading, and infection control rather than as a standalone treatment.
How the two are typically combined
In practice, standard wound care is the spine of any chronic wound plan and HBOT is a selective adjunct. A typical sequence: vascular and metabolic assessment, debridement of necrotic tissue, infection control (with deep tissue culture if indicated), offloading (total contact casting for plantar diabetic foot ulcers per IWGDF guidance), graduated compression for venous ulcers, and an evidence-based dressing matched to the wound bed. If the wound qualifies under NCD 20.29 and is not progressing after a documented period of optimized standard care, HBOT is considered. Throughout, the standard wound care plan continues — HBOT replaces nothing; it adds an oxygen-driven adjunct to the existing plan.
When to See a Wound Care Specialist
Patients with a chronic wound that is not measurably improving after several weeks of conservative care, a diabetic foot ulcer with deep involvement, exposed tendon or bone, or a history of radiation to the wound area, are typically best evaluated by a wound care clinician. The clinician can determine whether the wound meets evidence-based criteria for adjunctive HBOT and whether the standard-of-care plan can be optimized first. HBOT is not appropriate for every wound; matching the right patient to the right treatment is part of specialist evaluation.
People Also Ask
Common Questions
Will Medicare cover HBOT for my wound?
Medicare covers HBOT for the indications listed in National Coverage Determination 20.29. For chronic wounds, the most common pathway is a Wagner grade 3 or higher diabetic foot ulcer that has not responded to at least 30 days of well-documented standard care. Other covered indications include chronic refractory osteomyelitis, soft tissue radionecrosis, osteoradionecrosis, and compromised flaps or grafts. Coverage requires documentation of the qualifying indication, the standard-of-care plan, and ongoing reassessment of progress.
How many HBOT sessions are typical?
For chronic wound indications, the Undersea and Hyperbaric Medical Society describes courses of roughly 30 to 40 sessions, each about 90 minutes at 2.0–2.5 ATA, typically scheduled five days per week. The exact number depends on the indication and on how the wound responds. Sessions for emergencies (such as carbon monoxide poisoning or gas embolism) are very different — those are short, urgent courses rather than weeks of outpatient treatment.
Does HBOT replace debridement, offloading, and infection control?
No. HBOT is an adjunct to standard wound care, not a replacement. Major guideline bodies (UHMS, IWGDF, SVS/AVF) and the CMS coverage framework treat debridement, offloading, infection control, vascular optimization, and glycemic control as foundational. HBOT is layered on top of an optimized standard-of-care plan when the wound qualifies and is not progressing. Skipping the foundational steps and relying on HBOT alone is not evidence-based and is not how covered programs operate.
What are the risks or contraindications of HBOT?
The principal absolute contraindication is untreated pneumothorax. Relative cautions include certain chemotherapy agents (such as bleomycin and doxorubicin around the time of treatment), severe obstructive lung disease with bullae, severe claustrophobia, and active ear or sinus disease that prevents pressure equalization. Side effects can include reversible nearsightedness with prolonged courses, middle-ear barotrauma, and rare oxygen-related seizures. A hyperbaric medicine clinician reviews these risks individually before starting therapy.
If my wound is healing on standard care, do I still need HBOT?
Generally no. HBOT under NCD 20.29 is reserved for wounds that meet specific criteria and are not progressing on optimized standard care. A wound that is steadily improving on debridement, offloading, infection control, and appropriate dressings does not need HBOT. Adding HBOT to a wound that is already healing well does not have an evidence base, is unlikely to be covered, and exposes the patient to time, cost, and small but real procedural risks.
Related Services
References
- National Coverage Determination (NCD) 20.29 — Hyperbaric Oxygen Therapy — Centers for Medicare & Medicaid Services (CMS)
- UHMS Indications for Hyperbaric Oxygen Therapy — Undersea and Hyperbaric Medical Society (UHMS)
- Hyperbaric oxygen therapy for chronic wounds (Cochrane Systematic Review) — Cochrane Library
- IWGDF Guidelines on the Prevention and Management of Diabetes-Related Foot Disease — International Working Group on the Diabetic Foot (IWGDF)
- Hyperbaric Oxygen Therapy — Patient Reference — NIH MedlinePlus
General information, not medical advice. This page is educational. It does not create a physician-patient relationship and is not a substitute for evaluation, diagnosis, or treatment by a qualified clinician familiar with your individual history. If you have a wound that is worsening, severely painful, rapidly spreading, or accompanied by fever, seek in-person care or call 911. Please do not send protected health information (photos, medical records, diagnoses) through unencrypted email or web forms; call the clinic directly to discuss your situation.
Need a Real Evaluation, Not Just Information?
Dr. Rizvi sees patients across DFW with same- and next-day appointments. No referral required.